CGT Modality, Hybrid Models, And What To Keep In-House

This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech examining how modality changes the CGT manufacturing decision framework, with autologous programs requiring patient-specific coordination and allogeneic and in vivo approaches opening different paths for scale and inventory. It also defines four hybrid manufacturing archetypes and warns against fragmented models that create more complexity than clarity.